Nabilone for the treatment of medication overuse headache: Results of a preliminary double-blind, active-controlled, randomized trial

Journal of Headache and Pain

Volumn 13, Issue 8, 2012, Pages 677-684

  Pini, Luigi Alberto ^a   Guerzoni, Simona ^a   Cainazzo, Maria Michela ^a   Ferrari, Anna ^a   Sarchielli, Paola ^b   Tiraferri, Ilaria ^a   Ciccarese, Michela ^a   Zappaterra, Maurizio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cannabinoid; Medication overuse headache (MOH); Migraine; Nabilone; Treatment

Indexed keywords

IBUPROFEN; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; TRIPTAN DERIVATIVE;

ADULT; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; CLINICAL ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; FEMALE; HUMAN; MALE; MEMORY DISORDER; MIGRAINE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; STOMACH DISCOMFORT; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANTI-ANXIETY AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG OVERDOSE; FEMALE; HEADACHE DISORDERS, SECONDARY; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUALITY OF LIFE; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 84870314877     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-012-0490-1     Document Type: Article

References (34)

1. Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9:391-401
2. Meng ID, Dodick D, Ossipov MH, Porreca F (2011) Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies. Cephalalgia 31:851-860
3. Silberstein SD, Olesen J, Bousser MG et al (2005) The International Classification of Headache Disorders, 2nd edn (ICHD-II)-revision of criteria for 8.2 medication-overuse headache. Cephalalgia 25:460-465
4. Imai N, Kitamura E, Konishi T et al (2007) Clinical features of probable medication-overuse headache: A retrospective study in Japan. Cephalalgia 7:1020-1023
5. International Headache Society Classification Subcommittee (2004) International classification of headache disorders, 2nd edition. Cephalalgia 24:9-160
6. Diener HC, Limmroth V (2004) Medication-overuse headache: A worldwide problem. Lancet Neurol 3:475-483
7. Lantéri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review. Cephalalgia 31:837-850
8. Calabresi P, Cupini LM (2005) Medication-overuse headache: Similarities with drug addiction. Trends Pharmacol Sci 26:62-68
9. Fuh JL, Wang SJ, Lu SR, Juang KD (2005) Does medication overuse headache represent a behavior of dependence? Pain 119:49-55
10. Zeeberg P, Olesen J, Jensen R (2006) Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia 26:1192-1198
11. Hering R, Steiner TJ (1991) Abrupt outpatients withdrawal of medication in analgesic-abusing migraineurs. Lancet 337:1442-1443
12. Pini LA, Cicero AF, Sandrini M (2001) Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 21:878-883
13. Ayzenberg I, Obermann M et al (2006) Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 26:1106-1114
14. De Felice M, Ossipov MH, Porreca F (2011) Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol 24:193-196
15. Pinsger M, Schimetta W, Volc D et al (2006) Benefits of an addon treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain: A randomized controlled trial. Wien Klin Wochenschr 118:327-335
16. Wissel J, Haydn T, Muller J et al (2006) Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. J Neurol 253:1337-1341
17. Skrabek RQ, Galimova L, Ethans K et al (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9:164-173
18. Aggarwal SK (2012) Cannabinergic Pain Medicine: A Concise Clinical Primer and Survey ofRandomized-controlled Trial Results. Clin J Pain. (Epub 23 Feb). doi:10.1097/AJP.0b013e31824c5e4c
19. Lynch ME, Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72:735-744
20. Bestard JA, Toth CC (2011) An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract 11:353-368
21. Frank B, Serpell MG, Hughes J et al (2008) Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. BMJ 336:199-201
22. Fabre LF, McLendon D (1981) The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 21:377S-382S
23. Williamson EM, Evans FJ (2000) Cannabinoids in clinical practice. Drugs 60:1303-1314
24. Ware MA, St Arnaud-Trempe E (2010) The abuse potential of the synthetic cannabinoid nabilone. Addiction 105:494-503
25. Bedi G, Cooper ZD, Haney M (2012) Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol (Epub 19 Jan). doi: 10.1111/ j.1369-1600.2011.00427.x
26. Schulman EA, Lake AE 3rd, Goadsby PJ et al (2008) Defining refractory migraine and refractory chronic migraine: Proposed criteria from the refractory headache special interest section of the American headache society. Headache 48:778-782
27. Olesen J, Steiner T, Bousser MG et al (2009) Proposals for new standardized general diagnostic criteria for the secondary headaches. Cephalalgia 29:1331-1336
28. Ferrari A, Cicero AF, Bertolini A et al (2006) Need for analgesics/ drugs of abuse: A comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia 26:187-193
29. Raistrick D, Bradshaw J, Tober G et al (1994) Development of the Leeds Dependence Questionnaire (LDQ): A questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction 89:563-572
30. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
31. Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
32. Greco R, Gasperi V, Sandrini G et al (2010) Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia 30:296-302
33. Karschner EL, Darwin WD, McMahon RP et al (2011) Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89:400-407
34. Lionetto L, Negro A, Palmisani S, Gentile G et al. (2012) Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs (Epub Aug 3)